BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

938 related articles for article (PubMed ID: 33974165)

  • 1. Von Willebrand factor collagen-binding capacity predicts in-hospital mortality in COVID-19 patients: insight from VWF/ADAMTS13 ratio imbalance.
    Philippe A; Gendron N; Bory O; Beauvais A; Mirault T; Planquette B; Sanchez O; Diehl JL; Chocron R; Smadja DM
    Angiogenesis; 2021 Aug; 24(3):407-411. PubMed ID: 33974165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality.
    Philippe A; Chocron R; Gendron N; Bory O; Beauvais A; Peron N; Khider L; Guerin CL; Goudot G; Levasseur F; Peronino C; Duchemin J; Brichet J; Sourdeau E; Desvard F; Bertil S; Pene F; Cheurfa C; Szwebel TA; Planquette B; Rivet N; Jourdi G; Hauw-Berlemont C; Hermann B; Gaussem P; Mirault T; Terrier B; Sanchez O; Diehl JL; Fontenay M; Smadja DM
    Angiogenesis; 2021 Aug; 24(3):505-517. PubMed ID: 33449299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ADAMTS13-von Willebrand factor axis in COVID-19 patients.
    Mancini I; Baronciani L; Artoni A; Colpani P; Biganzoli M; Cozzi G; Novembrino C; Boscolo Anzoletti M; De Zan V; Pagliari MT; Gualtierotti R; Aliberti S; Panigada M; Grasselli G; Blasi F; Peyvandi F
    J Thromb Haemost; 2021 Feb; 19(2):513-521. PubMed ID: 33230904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ADAMTS13 activity to von Willebrand factor antigen ratio predicts acute kidney injury in patients with COVID-19: Evidence of SARS-CoV-2 induced secondary thrombotic microangiopathy.
    Henry BM; Benoit SW; de Oliveira MHS; Lippi G; Favaloro EJ; Benoit JL
    Int J Lab Hematol; 2021 Jul; 43 Suppl 1(Suppl 1):129-136. PubMed ID: 33270980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations between the von Willebrand Factor-ADAMTS13 Axis, Complement Activation, and COVID-19 Severity and Mortality.
    Sinkovits G; Réti M; Müller V; Iványi Z; Gál J; Gopcsa L; Reményi P; Szathmáry B; Lakatos B; Szlávik J; Bobek I; Prohászka ZZ; Förhécz Z; Mező B; Csuka D; Hurler L; Kajdácsi E; Cervenak L; Kiszel P; Masszi T; Vályi-Nagy I; Prohászka Z
    Thromb Haemost; 2022 Feb; 122(2):240-256. PubMed ID: 35062036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Von Willebrand factor and ADAMTS13 activity as clinical severity markers in patients with COVID-19.
    Marco A; Marco P
    J Thromb Thrombolysis; 2021 Aug; 52(2):497-503. PubMed ID: 33866481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levels and activities of von Willebrand factor and metalloproteinase with thrombospondin type-1 motif, number 13 in inflammatory bowel diseases.
    Cibor D; Owczarek D; Butenas S; Salapa K; Mach T; Undas A
    World J Gastroenterol; 2017 Jul; 23(26):4796-4805. PubMed ID: 28765701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imbalance of von Willebrand factor and ADAMTS13 axis is rather a biomarker of strong inflammation and endothelial damage than a cause of thrombotic process in critically ill COVID-19 patients.
    Joly BS; Darmon M; Dekimpe C; Dupont T; Dumas G; Yvin E; Beranger N; Vanhoorelbeke K; Azoulay E; Veyradier A
    J Thromb Haemost; 2021 Sep; 19(9):2193-2198. PubMed ID: 34219357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Von Willebrand Factor, ADAMTS13, and the Risk of Mortality: The Rotterdam Study.
    Sonneveld MA; Franco OH; Ikram MA; Hofman A; Kavousi M; de Maat MP; Leebeek FW
    Arterioscler Thromb Vasc Biol; 2016 Dec; 36(12):2446-2451. PubMed ID: 27737864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obstetric outcomes in pregnant COVID-19 women: the imbalance of von Willebrand factor and ADAMTS13 axis.
    Grandone E; Vimercati A; Sorrentino F; Colaizzo D; Ostuni A; Ceci O; Capozza M; Tiscia G; De Laurenzo A; Mastroianno M; Cappucci F; Fischetti L; Margaglione M; Cicinelli E; Nappi L
    BMC Pregnancy Childbirth; 2022 Feb; 22(1):142. PubMed ID: 35189860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. von Willebrand Factor Multimer Formation Contributes to Immunothrombosis in Coronavirus Disease 2019.
    Doevelaar AAN; Bachmann M; Hölzer B; Seibert FS; Rohn BJ; Bauer F; Witzke O; Dittmer U; Bachmann M; Yilmaz S; Dittmer R; Schneppenheim S; Babel N; Budde U; Westhoff TH
    Crit Care Med; 2021 May; 49(5):e512-e520. PubMed ID: 33591004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Von Willebrand factor, ADAMTS13 and mortality in dialysis patients.
    Ocak G; Roest M; Verhaar MC; Rookmaaker MB; Blankestijn PJ; Bos WJW; Fijnheer R; Péquériaux NC; Dekker FW
    BMC Nephrol; 2021 Jun; 22(1):222. PubMed ID: 34134634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the Diagnostic Value of Plasma Levels, Activities, and Their Ratios of von Willebrand Factor and ADAMTS13 in Patients with Cerebral Infarction.
    Qu L; Jiang M; Qiu W; Lu S; Zhao Y; Xia L; Ruan C; Zhao Y
    Clin Appl Thromb Hemost; 2016 Apr; 22(3):252-9. PubMed ID: 25916953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of von Willebrand factor high-molecular-weight multimers at acute phase is associated with detectable anti-ADAMTS13 IgG and neurological symptoms in acquired thrombotic thrombocytopenic purpura.
    Béranger N; Benghezal S; Savigny S; Capdenat S; Joly BS; Coppo P; Stepanian A; Veyradier A
    Thromb Res; 2019 Sep; 181():29-35. PubMed ID: 31330376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19.
    Turecek PL; Peck RC; Rangarajan S; Reilly-Stitt C; Laffan MA; Kazmi R; James I; Dushianthan A; Schrenk G; Gritsch H; Ewenstein BM; Mellgard B; Erdlenbruch W; Jain N; Binder NB; Mumford AD
    Thromb Res; 2021 May; 201():100-112. PubMed ID: 33662796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased von Willebrand factor ristocetin cofactor activity and increased ADAMTS13 antigen increase postoperative drainage after coronary artery bypass grafting.
    Mazur P; Plicner D; Zdziarska J; Sadowski J; Undas A
    Eur J Cardiothorac Surg; 2014 Feb; 45(2):e26-32. PubMed ID: 24351199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased VWF and Decreased ADAMTS-13 in COVID-19: Creating a Milieu for (Micro)Thrombosis.
    Favaloro EJ; Henry BM; Lippi G
    Semin Thromb Hemost; 2021 Jun; 47(4):400-418. PubMed ID: 33893632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The p.R1819_C1948delinsS mutation makes von Willebrand factor ADAMTS13-resistant and reduces its collagen-binding capacity.
    Daidone V; Saga G; Barbon G; Pontara E; Cattini MG; Morpurgo M; Zanotti G; Casonato A
    Br J Haematol; 2015 Aug; 170(4):564-73. PubMed ID: 25904363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe Plasmodium falciparum malaria is associated with circulating ultra-large von Willebrand multimers and ADAMTS13 inhibition.
    Larkin D; de Laat B; Jenkins PV; Bunn J; Craig AG; Terraube V; Preston RJ; Donkor C; Grau GE; van Mourik JA; O'Donnell JS
    PLoS Pathog; 2009 Mar; 5(3):e1000349. PubMed ID: 19300493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of von Willebrand factor and ADAMTS13 in patients with COVID-19: A systematic review and meta-analysis.
    Xu X; Feng Y; Jia Y; Zhang X; Li L; Bai X; Jiao L
    Thromb Res; 2022 Oct; 218():83-98. PubMed ID: 36027630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.